What the Evidence Does NOT Show Because the marketing around these compounds is expansive, it is worth stating explicitly what the published record does not establish: It does not show that cagrilintide is superior, equal, or inferior to tirzepatide no head-to-head trial exists, so any ranking is cross-trial inference
Our founder and medical director, Dr
Recently, the pharmacotherapy of MASLD mainly focuses on three parts of mechanisms: anti-inflammatory (ASK1 inhibitors), anti-diabetic (GCGR agonists, PPAR agonists), and prevention of lipotoxicity (FXR agonists, FGF21 analogues) (Wei et al., 2024)
Monitor for signs of dehydration or low blood sugar
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization